The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
Browsing Tag: Future of Biopharma
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...